CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
✉ Email this page to a colleague
All Clinical Trials for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04901117 ↗ | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days | Not yet recruiting | Heze Municipal 3rd people's hospital | Phase 4 | 2021-06-01 | The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group. |
| NCT04901117 ↗ | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days | Not yet recruiting | Jining No.2 People's Hospital | Phase 4 | 2021-06-01 | The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group. |
| NCT04901117 ↗ | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days | Not yet recruiting | Maternity and Child Care Health Center of Dezhou | Phase 4 | 2021-06-01 | The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group. |
| NCT04901117 ↗ | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days | Not yet recruiting | PKUcare luzhong hospital | Phase 4 | 2021-06-01 | The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Condition Name
Clinical Trial Locations for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Clinical Trial Progress for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Clinical Trial Phase
Clinical Trial Sponsors for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE
Sponsor Name
| Sponsor Name for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE | |
| Sponsor | Trials |
| Heze Municipal 3rd people's hospital | 2 |
| Maternity and Child Care Health Center of Dezhou | 2 |
| PKUcare luzhong hospital | 2 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
